drugset / Trial / NCT03792503
Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen
NaSingle-groupOpen-labelTreatment
Summary
In order to further improve the therapeutic efficacy of advanced no-squamous non-small cell lung cancer patients, improve the life cycle, this study will take the standard after treatment pemetrexed combined other anti-angiogenesis drugs to maintain as the direction, so as to provide more over the evidence for the treatment of advanced NSCLC.
Timeline
- Start
- 2019-02
- Primary completion
- 2020-02
- Completion
- 2022-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | — |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |